Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study.

In the present study, the HRs for GC recurrence of S-1 compared with those of CAPOX were below 1 in the subgroups of patients with stage III GC, at 0.873 (95% CI, 0.466–1.635; P=0.671) for stage IIIA, and 0.813 (95% CI, 0.482–1.371; P=0.437) for stage IIIC, although the HRs did not reach statistical significance.

also in 111,027 other papers